The combination of MDM2 (an E3-ubiquitin ligase involved in proteasomal degradation of p53) inhibitor (CGM097) and OTX015 results in p53 activation and decreased expression of MYC proteins, which synergistically promotes neuroblastoma cell death (79). Here, MDM2 is linked to neuroblastoma.